Research
Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce the risk of macroalbuminuria and renal function decline in patients with Type 2 Diabetes.
GLP-1 medications like semaglutide and liraglutide are not just for blood sugar; they also protect your kidneys. Studies show they significantly lower the risk of developing macroalbuminuria, a key marker of kidney damage.
GoodSupportsHIGH confidence
SUSTAIN-6 was a cardiovascular outcome trial that included semaglutide, and revealed beneficial effects on renal function, with a 46% lower risk of development of macroalbuminuria
Why this rating
Supported by multiple large cardiovascular outcome trials (LEADER, SUSTAIN-6, REWIND).
Source
Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Tomislav Bulum · Biomedicines · 2022
DOI 10.3390/biomedicines10102586
narrative_reviewCited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →